Receive alerts for 300+ data fields across thousands of companies. August 19, 2020. display: none !important; Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading... Fujifilm to invest 100 billion yen (928 million USD) to expand its large scale biologics production facility in Denmark, - Doubling the drug substance production capacity, FUJIFILM Diosynth Biotechnologies teams with COVID-19 Therapeutics Accelerator to reserve manufacturing capacity and provide technical expertise to deliver future COVID-19 therapies. How many offices does Fujifilm Diosynth Biotechnologies have? Tonix Pharmaceutical Holding Corp (NASDAQ:TNXP) has announced that FUJIFILM Diosynth Biotechnologies will be its manufacturing partner for its TNX-1800 coronavirus vaccine candidate. He added that the FDB team’s expertise on the manufacture of vaccinia could be useful in the manufacture of horsepox vaccines. FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics and gene therapy Contract Development and Manufacturing Organization (CDMO) has announced its participation as a founding member in a... FUJIFILM Diosynth Biotechnologies Announces $55 Million USD Investment To Expand Gene Therapy Development Capabilities, FUJIFILM Diosynth Biotechnologies will be expanding its gene therapy process and analytical development capabilities with the addition of new dedicated laboratories, FUJIFILM Diosynth Biotechnologies Named A 2019 Healthiest Employer, FUJIFILM Diosynth Biotechnologies receives top honors in Triangle Business Journal's 2019 Healthiest Employers Awards, Fujifilm Completes Acquisition of Biogen's Manufacturing Site in Denmark. }. The timeline maintains a robust cloning strategy with one round of cloning. Virtual ground-breaking ceremony held as planned expansion work begins . Meeson affirmed that the company can offer large scale manufacture of vaccines to meet demands during the pandemic. Fujifilm Diosynth Biotechnologies has 5 offices. The partnership will benefit Tonix as it will take advantage of FDB’s top technical experience in development as well as commercial cGMP manufacturing. Tonix Pharmaceutical Holding Corp (NASDAQ:TNXP) has announced that FUJIFILM Diosynth Biotechnologies will be its manufacturing partner for its TNX-1800 coronavirus vaccine candidate. Fujifilm To Acquire Large-Scale Biologics Manufacturing Site From Biogen To Accelerate Growth Of Its Bio CDMO Business. FUJIFILM Diosynth Biotechnologies ist ein spezialisiertes biopharmazeutisches CDMO-Unternehmen mit Entwicklungs- und Produktionsstandorten in Billingham und Redcar, Großbritannien; Research Triangle Park, North Carolina, USA und College Station, TX, USA, mit insgesamt über 1200 Mitarbeitern. This is because the estimated vaccine dose is quite low, and it is possible to offer vaccines with around 100 doses for every glass vial. The FDB manufacturing site is an ultramodern facility that has been designed to run a responsive and flexible contract manufacturing site. Learn about Craft real-time company insights . After my Master's in Journalism, I joined Bio Pharma Journal as a freelance writer and was soon promoted to an associate editor position. Fujifilm Diosynth Biotechnologies has offices in Morrisville, College Station, Miami, Hillerød and in 1 other location. According to the agreement, FUJIFILM Diosynth will offer contract manufacturing as well as development services supporting the … Tools. FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the expansion of its Monoclonal Antibody development and... Fujifilm Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Novel Anti-Staph Biologic, Fujifilm Diosynth Biotechnologies Expands Its Mammalian and Insect Cell Culture Capacity with Addition of 1,000L Single-Use Bioreactor. FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development... FUJIFILM Diosynth Biotechnologies Breaks Ground On A New BioCampus At Its Billingham, UK Location, Groundbreaking Ceremony held as work for the BioCampus development commences, FUJIFILM Diosynth Biotechnologies Announces Planned Leadership Succession, Steve Bagshaw to retire as CEO; Executive Committee appoints Martin Meeson, President & COO, FUJIFILM Diosynth Biotechnologies U.S.A as new Chief Executive Officer, FUJIFILM Diosynth Biotechnologies Expands Its Gene Therapy Manufacturing Capacity At Its College Station, Texas Location, Capacity increase will support production of high throughput and large volume gene therapy products, FUJIFILM Diosynth Biotechnologies Expands Its North Carolina Facility Cell Culture And Microbial Capacity, Groundbreaking Ceremony held as planned expansion work begins, FUJIFILM Diosynth Biotechnologies Named A Top Ten Healthiest Employer Nationally, Healthiest 100™ recognizes FUJIFILM Diosynth Biotechnologies as a top ten healthiest employer in nation, FUJIFILM Diosynth Biotechnologies Announces Its Participation As A Founding Member For The Establishment Of A New Center For Innovation And Manufacturing In Boston, Massachusetts. FUJIFILM Diosynth Biotechnologies Breaks Ground For Advanced Therapies Innovation Center In Texas. The company will come up with a manufacturing process, produce, and stock TNX-1800 at Tonix’s clinical development site at the FUJIFILM Diosynth’s College Station in Texas. Fujifilm hilft dabei, die Welt zu einem besseren, gesünderen und interessanteren Ort zu machen. FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) with experience focused on the development and manufacture of recombinant biopharmaceuticals and... FUJIFILM Diosynth Biotechnologies Announces New Service Offering to Support Development and cGMP Monoclonal Antibody Production. FUJIFILM Diosynth Biotechnologies arbeitet weltweit mit pharmazeutischen Unternehmen aus dem Bereich Biotechnologie zusammen, die neue Medikamente für die Bekämpfung von Krebs, Diabetes und seltenen Krankheiten entwickeln.